@article {7918,
	title = {CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group},
	journal = {Cancer Journal},
	volume = {13},
	year = {2007},
	note = {Cited By :9Export Date: 21 February 2017},
	month = {2007},
	pages = {327 - 334},
	abstract = {Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) improves outcomes in patients with previously untreated aggressive lymphomas. In a secondary analysis we evaluated the impact of adding rituximab to CEOP-14/CEOP-21 chemotherapy. Study Design: The trial opened in March 1999, and patients were randomly assigned to either CEOP-14 or CEOP-21. All patients enrolled from May 2002 onward received rituximab with each chemotherapy cycle, and those attaining a complete response received rituximab consolidation. Results: Complete and overall response rates in the CEOP-21 {\textpm} rituximab (N <= 114) and CEOP-14 {\textpm} rituximab (N <= 103) arms were similar, as were the overall survival (P <= 0.769) and time to progression distributions (P <= 0.969). Rituximab was shown to have a beneficial effect both on the overall survival and on the time to progression. Conclusions: Thus far, no significant improvement in outcome has been demonstrated with CEOP-14 {\textpm} rituximab versus CEOP-21 {\textpm} rituximab. However, with addition of rituximab to CEOP-21/CEOP-14, significant improvements in time to progression and overall survival were achieved. {\textcopyright} 2007 by Lippincott Williams \& Wilkins.},
	keywords = {Aggressive non-Hodgkin lymphoma, CEOP, Doseintensification, Overall survival, rituximab},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-38449114046\&doi=10.1097\%2fPPO.0b013e3181570170\&partnerID=40\&md5=b586a2bb82538d08b0675ea05974ac3c},
	author = {Economopoulos, T. and Psyrri, A. and Dimopoulos, M.A. and Kalogera-Fountzila, A. and N. Pavlidis and Tsatalas, C. and Nikolaides, C. and Mellou, S. and Xiros, N. and Fountzilas, G.}
}
